Human Papillomavirus Treatment Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Prevalence, Statistics, Revenue, Therapies, Companies by DelveInsight

(Albany, USA) DelveInsight's "Human Papillomavirus - Market Insight, Epidemiology, And Market Forecast - 2034′′ report offers an in-depth understanding of the human papillomavirus, historical and forecasted epidemiology as well as the human papillomavirus market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
The latest 7MM report uncovers crucial epidemiological patterns, transformative market trends, and highlights leading innovators like VLP The Vaccines Company SL, Voltron Therapeutics Inc., Rubius Therapeutics, Bristol-Myers Squibb, Precigen Inc., and Privo Technologies-all shaping the future of HPV prevention and treatment.

Some of the key facts of the Human Papillomavirus Market Report:
• According to DelveInsight, the human papillomavirus market in the 7MM is expected to experience significant growth during the study period from 2020 to 2034.
• According to the CDC, HPV is the most common sexually transmitted infection in the United States, with an oral HPV prevalence of 7.3% and high-risk HPV at 4.0% among adults aged 18-69 during 2011-2014.
• A study by Han et al. (2017) found that genital HPV infection affected 45.2% of men in the NHANES 2013-2014 survey, with low HPV vaccination rates of 10.7%.
• Available literature indicates that genital HPV prevalence is higher in men than in women.
• In February 2025, Precigen, Inc. announced that the FDA accepted its biologics license application (BLA) for PRGN-2012, an investigational gene therapy designed to treat HPV 6 and HPV 11-associated recurrent respiratory papillomatosis (RRP). The therapy received priority review, with a PDUFA date set for August 27, 2025.
• PRGN-2012 is designed to elicit immune responses against HPV-infected cells and has received Breakthrough Therapy Designation, Orphan Drug Designation, and an accelerated approval pathway from the FDA.
• In May 2024, Roche received FDA approval for its HPV self-testing kit, enabling early detection and improved diagnosis of HPV-related diseases.
• Key therapies in development for HPV include STP909, RTX-321, BVAC-C, GX-188E, ITI-2000, VGX-3100, ISA101, and others.
• Leading companies in the HPV treatment landscape include Inovio Pharmaceuticals, ISA Pharmaceuticals, Regeneron Pharmaceuticals, Merck, Pattern Pharma, Nykode, Vaccibody A/S, Turnstone Biologics, Advaxis, AstraZeneca, VLP The Vaccines Company SL, Voltron Therapeutics Inc., Rubius Therapeutics, Bristol-Myers Squibb, Precigen Inc., Privo Technologies, ViciniVax BV, Avalia Immunotherapies, BlueSky Immunotherapies, Cellid Co. Ltd, Cue Biopharma, Cullinan Oncology, Genexine, EyeGene, Hookipa Pharma, Immunomic Therapeutics, SQZ Biotechnologies, and others.

Request a sample to explore key market trends and future opportunities in the evolving human papillomavirus landscape across the 7MM @ https://www.delveinsight.com/sample-request/human-papillomavirus-hpv-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Human Papillomavirus Overview
Human Papillomavirus (HPV) is a group of more than 200 related viruses, many of which can infect the skin and mucous membranes. Some strains of HPV can lead to benign warts, while others are associated with various cancers, including cervical, anal, and oropharyngeal cancers. HPV is primarily transmitted through sexual contact and is one of the most common sexually transmitted infections worldwide. Although most infections are asymptomatic and clear on their own, persistent infection with high-risk HPV types can lead to cancer. Vaccination and screening are key strategies in preventing HPV-related cancers.

Human Papillomavirus Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Download the report to understand which factors are driving human papillomavirus epidemiology trends @ https://www.delveinsight.com/report-store/human-papillomavirus-hpv-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Human Papillomavirus Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Human Papillomavirus market or expected to be launched during the study period. The analysis covers the Human Papillomavirus market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the human papillomavirus pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

To know in detail about the human papillomavirus market outlook, drug uptake, treatment scenario, and epidemiology trends, Click here: https://www.delveinsight.com/report-store/human-papillomavirus-hpv-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Human Papillomavirus Market Strengths
• The availability of HPV vaccines, such as Gardasil, which offer protection against the most dangerous strains of the virus, is a significant strength in managing and preventing HPV-related diseases.
• Growing public health awareness about HPV's role in cancer prevention and the benefits of vaccination has led to higher vaccination rates, particularly among adolescents.

Human Papillomavirus Market Weaknesses
• Despite the effectiveness of vaccines, there are still regions, particularly in low- and middle-income countries, where access to HPV vaccination remains limited due to cost and infrastructure challenges.
• The stigma surrounding sexually transmitted infections like HPV can hinder individuals from seeking vaccination or screening, leading to lower prevention rates and delayed diagnoses.

Get a free sample for the human papillomavirus market Report: https://www.delveinsight.com/sample-request/human-papillomavirus-hpv-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Scope of the Human Papillomavirus Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Human Papillomavirus Therapies: STP909, RTX-321, BVAC-C, GX-188E, ITI-2000, VGX-3100, ISA101, and others.
• Key Human Papillomavirus Companies: Inovio Pharmaceuticals, ISA Pharmaceuticals, Regeneron Pharmaceuticals, Merck, Pattern Pharma, Nykode, Vaccibody A/S, Turnstone Biologics, Advaxis, AstraZeneca, VLP The Vaccines Company SL, Voltron Therapeutics Inc., Rubius Therapeutics, Bristol-Myers Squibb, Precigen Inc., Privo Technologies, ViciniVax BV, Avalia Immunotherapies, BlueSky Immunotherapies, Cellid Co. Ltd, Cue Biopharma, Cullinan Oncology, Genexine, EyeGene, Hookipa Pharma, Immunomic Therapeutics, SQZ Biotechnologies, and others.
• Human Papillomavirus Therapeutic Assessment: Human Papillomavirus currently marketed and Human Papillomavirus emerging therapies
• Human Papillomavirus Market Dynamics: Human Papillomavirus market drivers and Human Papillomavirus market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Human Papillomavirus Unmet Needs, KOL's views, Analyst's views, Human Papillomavirus Market Access and Reimbursement

To learn more about the key players and advancements in the human papillomavirus treatment Landscape, visit: https://www.delveinsight.com/sample-request/human-papillomavirus-hpv-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Table of Contents
1. Human Papillomavirus Market Report Introduction
2. Executive Summary for Human Papillomavirus
3. SWOT analysis of Human Papillomavirus
4. Human Papillomavirus Patient Share (%) Overview at a Glance
5. Human Papillomavirus Market Overview at a Glance
6. Human Papillomavirus Disease Background and Overview
7. Human Papillomavirus Epidemiology and Patient Population
8. Country-Specific Patient Population of Human Papillomavirus
9. Human Papillomavirus Current Treatment and Medical Practices
10. Human Papillomavirus Unmet Needs
11. Human Papillomavirus Emerging Therapies
12. Human Papillomavirus Market Outlook
13. Country-Wise Human Papillomavirus Market Analysis (2020-2034)
14. Human Papillomavirus Market Access and Reimbursement of Therapies
15. Human Papillomavirus Market Drivers
16. Human Papillomavirus Market Barriers
17. Human Papillomavirus Appendix
18. Human Papillomavirus Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Related Reports:
• Ventricular Fibrillation Market: https://www.delveinsight.com/report-store/supraventricular-tachycardia-market
• Acute Pulmonary Embolism Market: https://www.delveinsight.com/report-store/acute-pulmonary-embolism-market
• Human Papilomavirus Market: https://www.delveinsight.com/report-store/human-papillomavirus-hpv-market
• Acoustic Neuroma Market: https://www.delveinsight.com/report-store/acoustic-neuroma-market
• Fibrocystic Breast Condition Market: https://www.delveinsight.com/report-store/fibrocystic-breast-condition-market
• Ventricular Dysfunction Market: https://www.delveinsight.com/report-store/ventricular-dysfunction-market
• Immunologic Deficiency Syndrome Market: https://www.delveinsight.com/report-store/immunologic-deficiency-syndrome-market
• Healthcare Competitive Benchmarking: https://www.delveinsight.com/consulting/competitive-benchmarking-services
• Age-related Macular Degeneration Market: https://www.delveinsight.com/report-store/age-related-macular-degeneration-amd-market
• Interbody Cages Market: https://www.delveinsight.com/report-store/interbody-cages-market
• Burn Market: https://www.delveinsight.com/report-store/burns-market
• Hearing Implants Market: https://www.delveinsight.com/report-store/hearing-implants-market
• Advanced Cancer Pain Management Market: https://www.delveinsight.com/report-store/advanced-cancer-pain-management-market
• Diabetic Nephropathy Market: https://www.delveinsight.com/report-store/diabetic-nephropathy-market
• Dyspnea Market: https://www.delveinsight.com/report-store/dyspnea-market
• Eczema Market: https://www.delveinsight.com/report-store/eczema-market
• Implantable Infusion Pumps Market: https://www.delveinsight.com/report-store/implantable-infusion-pumps-market
• Menorrhalgia Market Size: https://www.delveinsight.com/report-store/menorrhalgia-market
• Pemphigus Vulgaris Market: https://www.delveinsight.com/report-store/pemphigus-vulgaris-market
• Tay-sachs Disease Or Gm2 Gangliosidosis Market: https://www.delveinsight.com/report-store/gm2-gangliosidosis-market
• Acute Lung Injury Market: https://www.delveinsight.com/report-store/acute-lung-injury-market
• Acute Radiation Syndrome Market: https://www.delveinsight.com/report-store/acute-radiation-syndrome-market
• Aids Related Kaposi's Sarcoma Market: https://www.delveinsight.com/report-store/aids-related-kaposis-sarcoma-market
• Anemia In Ckd Market: https://www.delveinsight.com/report-store/anemia-in-chronic-kidney-disease-market
• Aortic Aneurysm Stent Grafts Market: https://www.delveinsight.com/report-store/aortic-aneurysm-stent-grafts-market

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.